No Data
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -7.76% Cantor Fitzgerald $885 → $885 Reiterates Overweight → Overweight 07/11/2024 4.22%
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Eli Lilly (LLY) has an average outperform rating and a price target range of $540 to $1,100, according to analysts polled by Capital IQ.Price: 955.75, Change: +5.29, Percent Change: +0.56
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,025.According to TipRanks data, the analyst has a success rate of 59.5% and
loading...